Who we are
Newron is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Our scientific work centers around the development of novel therapeutic classes to address unmet needs in difficult-to-treat indications such as Parkinson’s disease, schizophrenia, and other underserved areas in which there has been limited innovation for decades.
Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, and has a subsidiary in Morristown, NJ, USA. With a heritage of more than 25 years of proprietary scientific research and clinical development, our experienced team of around 30 scientists, researchers, and clinicians brings drug candidates from discovery to commercialization.
Our success is rooted in strong clinical research and longstanding partnerships with specialized pharmaceutical companies, helping to bring novel treatments to patients worldwide. (find more here Science > Partnering).
What we do
Newron is committed to developing novel therapies for patients with diseases of the central and peripheral nervous system. We are looking to build our portfolio of products through in-house efforts as well as licensing and acquiring novel CNS compounds at various stages of development.
